https://www.selleckchem.com/pr....oducts/elacestrant.h
We aimed to describe long-term clinical outcomes in chronic hepatitis B (CH patients after HBsAg seroclearance, and identify factors that modify disease outcomes. CHB patients with HBsAg seroclearance occurring between 1986 and 2017 were recruited. Primary outcome was cirrhosis/hepatocellular carcinoma (HCC), and secondary outcomes were hepatic decompensation, liver-related death/transplantation, and all-cause mortality. Multivariable Cox model included demographics, prior antivirals, comorbidities, drugs (statins, metformin, prot
Like
Comment
Share
